Experienced leaders dedicated to excellence

Our purposefully selected leadership brings deep experience in developing and commercializing ophthalmic therapeutics, as well as founding and leading several companies in the eye care industry.

Bobak Azamian, MD, PhD
Bobak Azamian, MD, PhD
Co-founder, President, Director, and Chief Executive Officer

Bobby has served as President and CEO of Tarsus Pharmaceuticals since co-founding the company in 2017. In that time, Tarsus has established a leading team and culture, and completed successful fundraising efforts through an IPO and global partnerships. Tarsus continues to advance its pipeline into clinical studies, including its lead product, TP-03, which is now in Phase 3 clinical trials and commercial planning.

Bobby has co-founded and led two other novel therapeutics companies. Vibrato Medical, where he serves as Co-Chair, is developing a wearable treatment for peripheral arterial diseases, and has obtained NIH grant awards and Series A financing. Metavention, where he served as President and CMO through multiple clinical trials and Series A through C financings, is developing an interventional treatment for metabolic diseases.

Bobby began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer in numerous life sciences companies. He also served on the board of the nonprofit organization Octane.

Bobby trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received an MD from Harvard Medical School (Harvard-MIT Heath Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar, and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications. He enjoys sports, travel, and the arts, and spending time in Newport Beach with his wife, dog, and extended family.

Michael Ackermann, PhD
Michael Ackermann, PhD
Co-founder and Chairman

Michael is co-founder and Chairman of the Board of Tarsus. Michael also serves as Director of Biotechnology for the Stanford University Byers Center for Biodesign. Additionally, he is co-founder and former CEO of Presidio Medical, where he serves on the board. Previously, he was co-founder and served as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST). Prior to this, he was Vice President, Neurostimulation for Allergan (an AbbVie company), after serving as co-founder and CEO of Oculeve, Inc., which was acquired by Allergan. Michael received a BE degree in biomedical engineering from Vanderbilt University and a MS and PhD in biomedical engineering from Case Western Reserve University. He is a graduate of Stanford University’s Biodesign Fellowship and Vision Research Fellowship. Michael also has numerous patents and peer-reviewed publications.

Leo Greenstein
Leo Greenstein
Chief Financial Officer

Leo has more than 20 years of business and finance experience within life sciences, inclusive of the pharmaceutical, oncology diagnostics, and medical device sectors. His experience includes the assessment and completion of numerous equity and debt capital raises, investor relations and business development leadership. He has recruited and developed high-performing accounting and FP&A teams in the U.S. and Europe, designed scalable and SOX-compliant business processes, and implemented a variety of IT systems that have enhanced operational and finance capabilities and efficiencies across the organization. Prior to joining Tarsus, Leo served as Senior Vice President of Finance & Corporate Controller with Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).

Leo earlier served as Vice President of Finance & Corporate Controller with Endologix, Inc. (NASDAQ: ELGX), Senior Director of Finance with Clarient, Inc. (NASDAQ: CLRT), and Assistant Controller with Safeguard Scientifics, Inc. (NYSE: SFE). He earned his BA in Accounting from Arcadia University and his JD from Temple University Beasley School of Law. He is a Certified Public Accountant (license active in California) and is a member of the California State Bar.

Aziz Mottiwala
Aziz Mottiwala
Chief Commercial Officer

Aziz has over 20 years of biopharmaceutical industry leadership experience in several therapeutic areas, including over 10 years in the eye care space. Prior to joining Tarsus, Aziz was Chief Commercial Officer at Opiant Pharmaceuticals, overseeing all aspects of commercial strategy for the company’s addiction medicine portfolio. Before that, he was Senior Vice President and Head of Commercial at Avanir Pharmaceuticals. He also spent over 10 years at Allergan (an AbbVie company), most recently as Vice President of Marketing for the company’s eye care franchise, where he helped grow the business to over $2 billion in revenue across a diverse portfolio including Restasis® and Lumigan®, as well as several other devices and OTC product lines.

Previously, Aziz held commercial leadership roles at Valeant, IMS Health (now IQVIA), and Aventis Pharmaceuticals (now Sanofi). He received a BS in biochemistry from the University of California San Diego and an MBA in marketing and finance from the Marshall School of Business at the University of Southern California. He is also heavily active in the community and serves on the boards of the Orange County nonprofit OneOC and Octane.

Sesha Neervannan, PhD
Sesha Neervannan, PhD
Chief Operating Officer

Sesha has over 25 years of experience in the global development of novel therapeutics. Prior to joining Tarsus, he was a Senior Vice President of Global Pharmaceutical Development at Allergan (an AbbVie company), where he built strong and nimble early development functions to rapidly enable proofs of concept as well as a robust late-stage development organization for product approval and commercialization of small molecules and biologics. He also established industry-leading expertise in drug delivery technologies in multiple ocular, oral, and dermal product development programs; regulatory filings; and approvals, including novel intraocular, sustained-release injectables (Ozurdex®, Durysta®), a multidose non-preserved drug product in a first-ever container-closure delivery system (Restasis MultiDose®), topical dermal products (Rhofade® Cream, Aczone® Gel 7.5%), and several Rx and OTC topical ophthalmic products.

Prior to joining Allergan in 2007, Sesha was Director, Pharmaceutics R&D at Amgen Inc., where he oversaw CMC functions and assisted in building early development functions, primarily focusing on a discovery-development interface to enable pipeline advancement. Earlier in his career, he was Senior Research Investigator at Bristol-Myers Squibb Pharmaceutical Research Institute. He received his PhD in Pharmaceutical Chemistry from the University of Kansas. Sesha is active in community charity services and has served on the Board of Greater Irvine Chamber of Commerce, as well as on scientific advisory boards of non-profit organizations and start-up companies.

José Trevejo, MD, PhD
José Trevejo, MD, PhD
Chief Medical Officer

José brings his experience and passion for leading research and development teams in the advancement of novel therapeutics for serious and rare diseases. Before joining Tarsus, José served as Chief Development Officer for Rocket Pharmaceuticals and CEO of the non-viral gene therapy company SmartPharm, which was acquired in 2020. Prior to SmartPharm, he was Vice President, Clinical Development at Cyclerion Therapeutics where he helped advance a diverse clinical pipeline in GI, cardiac, and rare disease. José joined Ironwood/Cyclerion from Visterra, where he was a member of the Executive Team and led the pre-clinical and clinical development of novel biologics for infectious and rare diseases. Prior to Visterra, he held clinical development roles at Genentech and Vertex Pharmaceuticals.

José completed his clinical training including a sub-specialization in Infectious Disease at Brigham and Women’s Hospital/Beth-Israel Deaconess Medical Center/Harvard Medical School and earned his MD and PhD from the Tri-Institutional MD-PhD program at Cornell-Rockefeller-Sloan Kettering in New York City.

Bryan Wahl, MD, JD
Bryan Wahl, MD, JD
General Counsel

Bryan brings 15 years of legal experience and 20 years of medical experience, as both a legal counselor and medical practitioner. Prior to joining Tarsus, Bryan was a Partner at Knobbe Martens LLP, where he focused on intellectual property protection, infringement studies, and due diligence for financings and strategic transactions, specifically with respect to pharmaceutical, biotechnology, and medical device companies. Bryan counseled clients from the pre-Series A stage through exit, including Tarsus, which has been one of his clients since shortly after it was founded. In addition to his law practice, Bryan has practiced inpatient internal medicine since 2002, most recently as a per diem hospitalist with Kaiser Permanente, caring for patients both on hospital wards and in the ICU.

Prior to joining Knobbe Martens, Bryan entered medical school after one undergraduate year, and received his medical degree with honors from the University of Hawaii John A. Burns School of Medicine in 1999. He completed an internal medicine residency in the UCLA-affiliated Cedars-Sinai Medical Center program in Los Angeles in 2002, and is board certified in Internal Medicine. Bryan earned his law degree from the University of California, Berkeley School of Law in 2005. In law school, he received three American Jurisprudence Awards, two Prosser Awards, and the Barbee Fellowship, researching conflicts of interest of hospital institutional review boards, and was also a summer extern for the Honorable Ronald T.Y. Moon, Chief Justice of the Hawaii Supreme Court.

Dianne Whitfield
Dianne Whitfield
Chief Human Resources Officer

Dianne brings more than 20 years of experience in human resources, including over a decade of life sciences industry management and leadership. Prior to joining Tarsus, Dianne served as Vice President and Head of Human Resources for Evolus, Inc. (NASDAQ: EOLS), where she led efforts to support the commercialization of the start-up company’s first approved product. While at Evolus, she focused on recruiting top talent, building a positive culture, and fostering an effective employee experience in order to drive engagement and business results.

Prior to Evolus, Dianne held positions of increasing responsibility at Allergan (an AbbVie company), progressing to Director of Global Human Resources. Her experience there spanned a variety of human resources business partnership and leadership roles, where she supported both the Commercial and Research & Development organizations and led enterprise-wide initiatives in Global Talent Management. She has broad experience building organizations and supporting product launches in multiple therapeutic areas, including eye care, as well as expertise in developing culture and talent programs. Dianne holds a BA in psychology and social behavior from the University of California, Irvine and a Masters in social work from California State University, Long Beach.

Elizabeth Yeu, MD
Elizabeth Yeu, MD
Director and Chief Medical Advisor

Elizabeth is Chief Medical Advisor at Tarsus, partner at Virginia Eye Consultants, and Medical Director at Virginia Surgery Center. With more than two decades of experience in eye care, she’s authored hundreds of articles and conducted numerous lectures on subjects such as refractive cataract surgery, anterior segment reconstruction, and external disease management. Elizabeth provides guidance and governance across several national medical boards and committees, including as an examiner for the American Board of Ophthalmology and as the Chair of the Cataract Section of Ophthalmic News & Education (ONE) Network for the American Academy of Ophthalmology (AAO). Dr. Yeu is also an Executive Committee member and the current Secretary for the American Society of Cataract and Refractive Surgery (ASCRS) and, in 2023, she will become ASCRS President.

Elizabeth currently serves on the boards of Tarsus, STAAR Surgical, Ocular Science, Avellino Lab USA, and the Virginia Eye Foundation. She also serves as an Executive Board Member of CVP Physicians, Mid Atlantic. She earned her MD through an accelerated and combined undergraduate/medical school program at the University of Florida College of Medicine. Elizabeth completed her ophthalmology residency at Rush University Medical Center in Chicago, where she served as Chief Resident (2006-2007). She then accepted a fellowship in Cornea, Anterior Segment, and Refractive Surgery at the Cullen Eye Institute, Baylor College of Medicine (2007-2008), where she also served as an Assistant Professor (2008-2013). Elizabeth continues to train residents as Assistant Professor of Ophthalmology at Eastern Virginia Medical School.

Mark Holdbrook
Mark Holdbrook
SVP, Clinical Affairs

Mark has over 40 years of experience in the design, execution, analysis, and reporting of clinical trials. He has experience in epidemiology as well as in the medical device, biotechnology, and pharmaceutical industries. His therapeutic areas of expertise include ophthalmology, cardiology, oncology, orthopedics, gynecology, and dermatology. Most recently, he was the Senior Director of Clinical Affairs and Biostatistics at Oculeve, Inc., where he led the successful clinical development of the TrueTear® device. Prior to Oculeve, he was the Vice President of Clinical Affairs, Data Management, and Biostatistics for Experien Group, LLC, a medical device consulting firm. He also spent 10 years at Santen, Inc. in various positions developing ophthalmic pharmaceuticals.

Mark holds a BA from the University of California at San Diego

Arthur Chan, PhD
Arthur Chan, PhD
VP, Medical Affairs

Arthur has over 18 years of pharmaceutical and medical device experience and came to Tarsus from Novartis where he was Lead Medical Director, overseeing the anterior segment medical affairs team and their dry eye and refractive products, including Xiidra®. Prior to this role, he was the Executive Director of Medical Science Liaison (MSL) capabilities, managing MSL training and medical/legal/regulatory review across all of Novartis’ franchises. Previously, as Head of Medical Science at Alcon, Arthur built and led the company’s first surgical MSL team, supporting Alcon’s surgical suite, intraocular lenses, and the entire cataract, refractive, glaucoma and retina portfolio. Arthur began his career at Insightec, a start-up company where he was part of a team that managed the clinical trials, physician training, and PMA process that led to the world’s first FDA-approved, image-guided focused ultrasound surgery device. He transitioned into eye care when he joined Bausch and Lomb as a Medical Liaison, launching Lotemax Gel and Prolensa.

Arthur received his BS in mechanical engineering from the University of Alberta, a PhD in biomedical engineering from the University of Washington, and an executive MBA with a specialty in pharmaceutical and healthcare marketing from St. Joseph’s University. He holds multiple patents, is a graduate of the University of Washington’s Technology Entrepreneurship Program, and was a WRF Capital Gates Foundation fellow involved with turning UW technology into start-up companies. He is currently an adjunct professor at St. Joseph’s University’s Haub School of Business and is on the advisory boards of the MSL Society and Fierce Pharma’s Medical Affairs Summit. Arthur is the 2021 recipient of the Ophthalmic World Leaders’ Catalyst Award, a peer recognition given to an individual that contributed significantly to helping others advance their careers in eye care while advancing diversity, equity, and inclusion in the field.

Neera Clase
Neera Clase
VP, Market Access

Neera has more than 20 years of biopharmaceutical leadership experience across multiple therapeutic areas spanning access and reimbursement, business development, and sales and marketing. Her experience includes successfully launching 10+ products across multiple therapeutic areas at both large pharma and small biotech companies.

Prior to joining Tarsus, Neera was most recently the Vice President of Access and Reimbursement at Acadia Pharmaceuticals. Before that, Neera was at Relypsa Pharmaceuticals, where she established the payer strategy and built the managed markets team. She has been involved with multiple first-in-class product launches and is responsible for leading the commercial access and reimbursement functions to successfully support these launches. Neera has broad reimbursement experience in both the small molecule and medical device areas focusing on payers, distribution, patient support services, lifecycle management, and pricing and contracting.

Before working in biopharmaceutical start-ups, Neera had a 15-year career at Abbott Laboratories, where she held a variety of positions of increasing responsibility, progressing to the General Manager of Market Access for Abbott Diabetes Care. Neera received her BA in life sciences/psychology from Indiana State University and her MSW from the Indiana University School of Social Work.

Kavita Dhamdhere, MD, PhD
Kavita Dhamdhere, MD, PhD
VP, Clinical Development

Kavita has over 15 years of clinical development experience in ophthalmology and vision care spanning across dry eye disease, refractive and cataract surgery equipment, contact lenses, intraocular lens, and glaucoma. Prior to Tarsus, Kavita was Head of Clinical Development at Sight Sciences where she oversaw clinical, medical, and innovation initiatives for the dry eye and surgical glaucoma platforms. During her successful tenure at Sight Sciences, she led a high-performing clinical team and developed the clinical strategy, a robust evidence package, and indication expansions. Prior to Sight Sciences, Kavita worked at Allergan as a clinical scientist, prior to which she worked at Abbott Medical Optics and J&J.

Kavita earned her MD in India and practiced as a comprehensive ophthalmologist before completing her PhD from UC Berkeley. Her academic research was focused on dry eye and blepharitis during residency and on discovery of novel disease markers of diabetic retinopathy during her PhD. She has participated as a principal investigator or co-investigator in many clinical trials and conducted many laboratory investigations in both academic and private practice settings. She also serves as a reviewer for numerous journals focusing on ophthalmology, current eye research, and managed care. She continues to serve as a surgeon through mission work across India in underprivileged and tribal areas.

Mark Luz
Mark Luz
VP, Strategy and Commercial Ops

Mark Luz has more than 15 years of strategy, finance, and analytics experience. Prior to joining Tarsus, Mark served as Vice President, Finance, and Strategic Analytics at Dermavant Sciences where he drove planning and strategy behind the commercialization of VTAMA. Prior to Dermavant, Mark worked at Avanir Pharmaceuticals where he was Senior Director of Analytics and Insights, driving analytics leadership and data-driven decisions across the organization. Previously, he held finance and payer leadership roles at UnitedHealthcare/OptumRx and a series of financial planning and strategy leadership roles in the financial services industry. Mark has a bachelor’s degree in finance from Arizona State University and an MBA from the University of Southern California.

Matt Rossen
Matt Rossen
VP, Marketing

Matt has over 20 years of commercial experience across a range of therapeutic categories, including CNS, sleep science, hematology, and oncology. Before joining Tarsus, Matt served as Vice President of Marketing for QED Therapeutics (a BridgeBio company), where he established the commercial infrastructure and led cross-functional launch planning efforts for Truseltiq, QED’s first approved therapeutic. Prior to QED, Matt served in roles of increasing responsibility at Jazz Pharmaceuticals, including as Marketing Director for Xyrem (sleep science), Head of Marketing for the Hematology portfolio, and as Senior Director of Business Development. Prior to Jazz, Matt worked at Pfizer across several commercial functions such as commercial operations, US and global marketing, and commercial development.

Matt holds his BA in Kinesiology and Human Physiology from the University of Colorado and obtained his MBA from New York University.

Benir Ruano
Benir Ruano
VP, Manufacturing and Supply Chain

Benir has more than 35 years of pharmaceutical and biotech/device experience developing, manufacturing, and commercializing novel therapeutics and delivery systems. Previously, Benir was Vice President, Global Manufacturing and Technical Operations at Xeris Pharmaceuticals where he developed early through late clinical phase drug products, including a pipeline of small molecules, biologics, and combination products. He oversaw global networks of contract manufacturers, packagers, and service providers, as well as gained FDA, EMA/EC, and other approvals for new products.

Prior to Xeris, Benir was Vice President, Manufacturing Operations, Supply Chain, and Technical Development at Cell Therapeutics (CTI BioPharma) where he developed and commercialized oncology products in the United States and Europe. He was also Senior Director at OSI Pharmaceuticals (Eyetech Pharma) where he oversaw CMOs, as well as launched and commercialized Macugen (a novel anti-VEGF oligonucleotide for AMD, diabetic macular edema, and diabetic retinopathy).

Benir earned his bachelor’s degree at UC San Diego, his MBA from National University, and is a certified Lean Six Sigma Black Belt.

Scott Youmans
Scott Youmans
VP, Sales

Scott has more than 20 years of pharmaceutical sales leadership, training and marketing experience with most of that time in eye care. With a strong focus on sales leadership, he has a long history of building high-performing teams. Scott also has significant experience in training and marketing, giving him a unique and broad commercial perspective.

Prior to joining Tarsus, Scott served as Regional Sales Director for Allergan’s specialty eye care team where his strategic leadership and strong customer focused culture quickly translated to high-performing results. Before that, Scott restructured the eye care training team to meet the needs of a diversifying organization and created a new level of training across a diverse product portfolio that included surgical, injectable and topical businesses. He also spent significant time helping to lead the professional marketing efforts for Restasis during an unprecedented period of product growth. Scott’s foundation in eye care and understanding of customer needs began as a frontline sales leader calling on customers in the mid-Atlantic region of the United States.

Prior to his nearly 15 years at Allergan, Scott worked as a frontline sales leader and sales rep at Forest Laboratories. He earned his BA in Biology and received his MBA at Lehigh University.

Adrienne Kemp
Adrienne Kemp
Senior Director, Corporate Communications

Adrienne has more than 20 years of PR and leadership experience in the health care industry, providing strategic oversight and communications support for multiple pharmaceutical, biotechnology, and medical device brands and companies.

She has worked across multiple therapeutic areas, including ophthalmology, oncology, rare diseases, women’s health, diabetes, and aesthetics as a senior consultant to support strategic planning, corporate and product communications, advocacy relations, and stakeholder engagement for several companies including Galderma, ZELTIQ (now Allergan), Bayer Healthcare, Onyx Pharmaceuticals (now Amgen) and Vertex Pharmaceuticals.

Adrienne has held global communications and corporate affairs positions at Edwards Lifesciences and Abbott Diabetes Care, where she managed PR and communications strategy, executive visibility programming, and professional relations. Earlier, Adrienne served in senior level positions at Ketchum and W2O (now Real Chemistry), providing media strategy and communications support for the launch of several key products on behalf of Genentech, Medtronic, and Dendreon.

Adrienne holds a BA from the University of California, Los Angeles (UCLA).

David Nakasone
David Nakasone
Senior Director, Investor Relations

David has more than 10 years of investor relations experience and has an extensive background in developing and implementing strategic programs within the life sciences space. Before joining Tarsus, David spent 3 years at Ionis Pharmaceuticals, a leader in RNA-targeted drug discovery and development, where he led investor targeting and outreach. Prior to Ionis, David worked at Allergan (now an AbbVie company), where he worked closely with executive management to communicate key corporate messages in a consistent and strategic manner. His responsibility, interfacing between Allergan and the investment community, was instrumental in creating one of the world’s top 10 pharmaceutical companies.

A Certified Public Accountant (license inactive in California), David holds a Bachelor of Science in Business Administration from San Diego State University.

Michael Ackermann, PhD
Co-founder and Chairman

Michael is co-founder and Chairman of the Board of Tarsus. Michael also serves as Director of Biotechnology for the Stanford University Byers Center for Biodesign. Additionally, he is co-founder and former CEO of Presidio Medical, where he serves on the board. Previously, he was co-founder and served as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST). Prior to this, he was Vice President, Neurostimulation for Allergan (an AbbVie company), after serving as co-founder and CEO of Oculeve, Inc., which was acquired by Allergan. Michael received a BE degree in biomedical engineering from Vanderbilt University and a MS and PhD in biomedical engineering from Case Western Reserve University. He is a graduate of Stanford University’s Biodesign Fellowship and Vision Research Fellowship. Michael also has numerous patents and peer-reviewed publications.

Bobak Azamian, MD, PhD
Co-founder, President, Director, and Chief Executive Officer

Bobby has served as President and CEO of Tarsus Pharmaceuticals since co-founding the company in 2017. In that time, Tarsus has established a leading team and culture, and completed successful fundraising efforts through an IPO and global partnerships. Tarsus continues to advance its pipeline into clinical studies, including its lead product, TP-03, which is now in Phase 3 clinical trials and commercial planning.

Bobby has co-founded and led two other novel therapeutics companies. Vibrato Medical, where he serves as Co-Chair, is developing a wearable treatment for peripheral arterial diseases, and has obtained NIH grant awards and Series A financing. Metavention, where he served as President and CMO through multiple clinical trials and Series A through C financings, is developing an interventional treatment for metabolic diseases.

Bobby began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer in numerous life sciences companies. He also served on the board of the nonprofit organization Octane.

Bobby trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received an MD from Harvard Medical School (Harvard-MIT Heath Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar, and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications. He enjoys sports, travel, and the arts, and spending time in Newport Beach with his wife, dog, and extended family.

Bhaskar Chaudhuri, PhD
Director

Bhaskar has been Operating Partner at Frazier Healthcare Partners since 2011. He brings significant operational experience in drug research, development, and commercialization in the United States, Europe, and emerging markets to the Life Science team. He also leads investments in later-stage companies as well as in international opportunities and is a co-founder of Arcutis (NASDAQ: ARQT), where he currently serves on the board. Bhaskar also serves on the board of Teligent (NASDAQ: TLGT) and is an advisor to the Johns Hopkins Berman Institute of Bioethics. He formerly served on the boards of directors of Silvergate Pharmaceuticals (acquired by CutisPharma, now known as Azurity), Corium International (acquired by Gurnet Point Capital), and Thesan Pharmaceuticals.

Prior to joining Frazier, Bhaskar was President of Valeant Pharmaceuticals, where he led the company’s international operations and business development activities. He joined Valeant through its acquisition of Dow Pharmaceutical Sciences, where he had been President and CEO. Before Dow, Bhaskar worked at Mylan Pharmaceuticals in several capacities, including EVP of Scientific Affairs at Bertek Pharmaceuticals, a Mylan subsidiary, and as General Manager of the Dermatology Division. Earlier, he worked at Penederm, a skincare and drug-delivery company, as VP of R&D. Bhaskar holds a PhD in pharmaceutics, an MS in industrial pharmacy, and a BS in pharmacy.

Rosemary Crane
Director

Rose has more than 30 years of extensive experience in the pharmaceutical industry, including executive leadership, board service, innovation, business development, and global commercialization. She brings significant executive leadership and operating expertise to the Tarsus board, having previously served as President and Chief Executive Officer of both MELA Sciences, Inc. (now Strata Skin Sciences) and epocrates, as well as Partner and Head of Commercialization at Appletree Partners. Prior to that, Rose held several senior executive positions at Johnson & Johnson, including Group Chairman, OTC & Nutritional Group, leading the largest worldwide OTC company. Earlier in her career, she spent 20 years at Bristol Myers Squibb, completing her tenure as President, US Primary Care.

Rose currently sits on the boards of Teva Pharmaceuticals Industries Ltd. and Catalent, Inc., as well as acts as a director of the Hackensack Meridian Health Center for Discovery and Innovation. Previously, she served on the boards of several pharmaceutical and life sciences companies, including Edge Therapeutics, Inc., Unilife Corporation, Cipher Pharmaceuticals Inc., Targanta Therapeutics Corp., and Zealand Pharma A/S. Rose received a BA in both communications and English from the State University of New York at Oswego and an MBA from Kent State University.

Andrew Goldberg, MD
Director

Andrew is a Managing Director at Marshall Wace and helps lead the XO Healthcare Innovation fund, which focuses on late-stage private investments. Before this he was a Partner on the private innovation team at Palo Alto-based Vivo Capital, where he focused on private pharmaceutical and medical device companies. Prior to Vivo, he worked at McKinsey & Company in their Silicon Valley office in their pharmaceutical and medical products practice. He has served on the boards of several healthcare companies, including Swift Health Systems Inc (Chairman), Ossium Health (Director), Arcutis Biotherapeutics (NASDAQ: ARQT) (Observer), Instil Bio (NASDAQ: TIL) (Observer), Harmony Biosciences (NASDAQ: HRMY) (Observer), Neocis (Observer) and Impel Neuropharma (NASDAQ: IMPL) (Observer). Other representative investments include River Vision (acquired by Horizon).

Andrew is a US board-certified physician in both Critical Care Medicine and Emergency Medicine. He received his MD from The George Washington University School of Medicine in Washington, DC, and has held academic and clinical appointments at the Mayo Clinic, Stanford VA Palo Alto Medical Center, Oregon Health & Science University, the University of Arizona, and the Washington Township Medical Foundation.

 

William J. Link, PhD
Director

Bill is Founder and Managing Partner of Flying L Partners and a Founder and Managing Director of Versant Ventures. He has over two decades of operations experience in the healthcare industry and specializes in early-stage investing in medical devices. Prior to co-founding Versant Ventures, Bill was a general partner at Brentwood Venture Capital. He was previously Founder, Chairman, and CEO of Chiron Vision, which was sold to Bausch and Lomb in 1997. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics, a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the board of their successor company, Advanced Medical Optics, which was acquired by Abbott in 2009 and then by Johnson and Johnson in 2016.

Before entering the healthcare industry, he was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Bill currently serves on the boards of several private companies. He previously served on the board of Edwards Lifesciences (NYSE: EW), Glaukos (NYSE: GKOS) and Oyster Point Pharma, Inc. (NASDAQ: OYST). He received his BS, MS, and PhD from Purdue University.

Wendy Yarno
Director

Wendy has more than 30 years of experience in the biopharmaceutical industry, as a public company director and product commercialization leader, including 26 years at Merck & Co. Inc. While at Merck, she held positions of increasing seniority, most recently as Chief Marketing Officer. In that position, she led a global organization charged with all aspects of commercialization of pharmaceuticals in more than 20 therapeutic areas. She also served as General Manager, Cardiovascular/Metabolic US Business Unit, and as Merck’s Senior Vice President of Human Resources. Earlier in her career, she was Vice President of the Women’s Healthcare franchise for Johnson & Johnson’s Ortho-McNeil Pharmaceutical subsidiary.

She has served on the boards of several public and private biotechnology and medical device companies, including St. Jude Medical, Medivation, Alder Biopharmaceuticals, Aratana Therapeutics, and Myokardia. She currently serves on the boards of Global Blood Therapeutics, Ideaya Biosciences, and Inovio Pharmaceuticals. She received a BS in business administration from Portland State University and an MBA from Temple University, Fox School of Business.

Elizabeth Yeu, MD
Director and Chief Medical Advisor

Elizabeth is Chief Medical Advisor at Tarsus, partner at Virginia Eye Consultants, and Medical Director at Virginia Surgery Center. With more than two decades of experience in eye care, she’s authored hundreds of articles and conducted numerous lectures on subjects such as refractive cataract surgery, anterior segment reconstruction, and external disease management. Elizabeth provides guidance and governance across several national medical boards and committees, including as an examiner for the American Board of Ophthalmology and as the Chair of the Cataract Section of Ophthalmic News & Education (ONE) Network for the American Academy of Ophthalmology (AAO). Dr. Yeu is also an Executive Committee member and the current Secretary for the American Society of Cataract and Refractive Surgery (ASCRS) and, in 2023, she will become ASCRS President.

Elizabeth currently serves on the boards of Tarsus, STAAR Surgical, Ocular Science, Avellino Lab USA, and the Virginia Eye Foundation. She also serves as an Executive Board Member of CVP Physicians, Mid Atlantic. She earned her MD through an accelerated and combined undergraduate/medical school program at the University of Florida College of Medicine. Elizabeth completed her ophthalmology residency at Rush University Medical Center in Chicago, where she served as Chief Resident (2006-2007). She then accepted a fellowship in Cornea, Anterior Segment, and Refractive Surgery at the Cullen Eye Institute, Baylor College of Medicine (2007-2008), where she also served as an Assistant Professor (2008-2013). Elizabeth continues to train residents as Assistant Professor of Ophthalmology at Eastern Virginia Medical School.

Contact Tarsus

Please reach out to us using the form below.

"*" indicates required fields

Opt-in
This field is for validation purposes and should be left unchanged.